Abstract
The pharmacokinetics and urinary metabolic profile of R and S-warfarin, following administration of a 1.5 mg/kg oral dose of racemic warfarin, alone and 4 days into an oral regimen of 100 mg phenylbutazone three times a day, was investigated in three volunteers using a stereospecific h.p.l.c. fluorescent assay. The mean elimination half-life of S-warfarin was increased from 25 to 46 h during phenylbutazone administration, whilst that of the R-isomer was decreased from 37 to 25 h. The peak unbound concentrations of both warfarin enantiomers were higher during phenylbutazone administration, due to displacement. Displacement was not stereoselective. The unbound clearance of more potent S-warfarin is decreased by four-fold during phenylbutazone administration, due to substantial inhibition of both 6- and 7-hydroxylation, significant pathways of elimination of S-warfarin in the absence of phenylbutazone. The unbound clearance of R-warfarin is almost unchanged during phenylbutazone administration, due to the marginal effect of phenylbutazone on 6- and 7-hydroxylation, themselves minor pathways of elimination of this enantiomer in the absence of phenylbutazone. The stereoselective reduction of S- and R-warfarin, to their respective SS and RS-alcohols, is also substantially inhibited during phenylbutazone administration. Collectively the data point to the complex effect of phenylbutazone administration on warfarin's pharmacokinetics.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aarons L. J., Rowland M. Kinetics of drug displacement interactions. J Pharmacokinet Biopharm. 1981 Apr;9(2):181–190. doi: 10.1007/BF01068081. [DOI] [PubMed] [Google Scholar]
- Aggeler P. M., O'Reilly R. A., Leong L., Kowitz P. E. Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med. 1967 Mar 2;276(9):496–501. doi: 10.1056/NEJM196703022760904. [DOI] [PubMed] [Google Scholar]
- Breckenridge A., Orme M. Kinetics of warfarin absorption in man. Clin Pharmacol Ther. 1973 Nov-Dec;14(6):955–961. doi: 10.1002/cpt1973146955. [DOI] [PubMed] [Google Scholar]
- Eichelbaum M., Somogyi A., von Unruh G. E., Dengler H. J. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol. 1981 Jan;19(2):133–137. doi: 10.1007/BF00568400. [DOI] [PubMed] [Google Scholar]
- Fasco M. J., Vatsis K. P., Kaminsky L. S., Coon M. J. Regioselective and stereoselective hydroxylation of R and S warfarin by different forms of purified cytochrome P-450 from rabbit liver. J Biol Chem. 1978 Nov 10;253(21):7813–7820. [PubMed] [Google Scholar]
- Hewick D. S., McEwen J. Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man. J Pharm Pharmacol. 1973 Jun;25(6):458–465. doi: 10.1111/j.2042-7158.1973.tb09133.x. [DOI] [PubMed] [Google Scholar]
- Lewis R. J., Trager W. F., Chan K. K., Breckenridge A., Orme M., Roland M., Schary W. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974 Jun;53(6):1607–1617. doi: 10.1172/JCI107711. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lewis R. J., Trager W. F. The metabolic fate of warfarin: studies on the metabolites in plasma. Ann N Y Acad Sci. 1971 Jul 6;179:205–212. doi: 10.1111/j.1749-6632.1971.tb46900.x. [DOI] [PubMed] [Google Scholar]
- Nagashima R., Levy G. Comparative pharmacokinetics of coumarin anticoagulants. V. Kinetics of warfarin elimination in the rat, dog, and rhesus monkey compared to man. J Pharm Sci. 1969 Jul;58(7):845–849. doi: 10.1002/jps.2600580711. [DOI] [PubMed] [Google Scholar]
- O'Reilly R. A., Motley C. H. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Ann Intern Med. 1979 Jul;91(1):34–36. doi: 10.7326/0003-4819-91-1-34. [DOI] [PubMed] [Google Scholar]
- O'Reilly R. A. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med. 1976 Aug 12;295(7):354–357. doi: 10.1056/NEJM197608122950702. [DOI] [PubMed] [Google Scholar]
- O'Reilly R. A., Trager W. F., Motley C. H., Howald W. Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man. J Clin Invest. 1980 Mar;65(3):746–753. doi: 10.1172/JCI109722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Oie S., Guentert T. W., Tozer T. N. Effect of saturable binding on the pharmacokinetics of drugs: a simulation. J Pharm Pharmacol. 1980 Jul;32(7):471–477. doi: 10.1111/j.2042-7158.1980.tb12971.x. [DOI] [PubMed] [Google Scholar]
- Pohl L. R., Nelson S. D., Porter W. R., Trager W. F., Fasco M. J., Baker F. D., Fenton J. W., 2nd Warfarin-stereochemical aspects of its metabolism by rat liver microsomes. Biochem Pharmacol. 1976 Oct 1;25(19):2153–2162. doi: 10.1016/0006-2952(76)90127-1. [DOI] [PubMed] [Google Scholar]
- Pohl L. R., Porter W. R., Trager W. F. Stereochemical biotransformation of warfarin as a probe of the homogeneity and mechanism of microsomal hydroxylases. Biochem Pharmacol. 1977 Jan 15;26(2):109–114. doi: 10.1016/0006-2952(77)90380-x. [DOI] [PubMed] [Google Scholar]
- Sellers E. M., Koch-Weser J. Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci. 1971 Jul 6;179:213–225. doi: 10.1111/j.1749-6632.1971.tb46901.x. [DOI] [PubMed] [Google Scholar]
- Silber B., Riegelman S. Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma. J Pharmacol Exp Ther. 1980 Dec;215(3):643–648. [PubMed] [Google Scholar]
- Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]